Acamprol: Effective Relief for Alcohol Dependence Symptoms
| Product dosage: 333 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.08 | $62.46 (0%) | 🛒 Add to cart |
| 60 | $1.90 | $124.92 $113.83 (9%) | 🛒 Add to cart |
| 90 | $1.43 | $187.37 $128.95 (31%) | 🛒 Add to cart |
| 120 | $1.19 | $249.83 $143.05 (43%) | 🛒 Add to cart |
| 180 | $1.05
Best per pill | $374.75 $189.39 (49%) | 🛒 Add to cart |
Synonyms | |||
Acamprol (acamprosate calcium) is a prescription medication specifically formulated to support the maintenance of abstinence in alcohol-dependent patients who have achieved initial sobriety. It functions by helping to restore the natural balance of neurotransmitters in the brain, which are often disrupted by chronic alcohol use. This pharmacological action aids in reducing the psychological distress and physiological cravings associated with alcohol withdrawal, thereby supporting long-term recovery goals. Clinical studies and extensive post-marketing surveillance have established its efficacy and safety profile when used as part of a comprehensive treatment plan that includes psychosocial support.
Features
- Active ingredient: Acamprosate calcium 333 mg
- Delayed-release tablet formulation for consistent plasma levels
- Designed for oral administration, to be taken with water
- Typically packaged in calendar blister packs to support adherence
- Requires no hepatic metabolism; eliminated renally unchanged
- Compatible with most comprehensive addiction treatment protocols
Benefits
- Reduces the frequency and intensity of cravings for alcohol in abstinent patients.
- Helps stabilize brain chemistry, mitigating the dysphoria and anxiety common in early recovery.
- Supports long-term abstinence when combined with counseling and behavioral therapies.
- Does not produce sedation, euphoria, or other psychoactive effects that could impair daily functioning.
- Provides a non-addictive, pharmacological cornerstone for a sustained recovery program.
- Demonstrated efficacy in numerous randomized, double-blind, placebo-controlled clinical trials.
Common use
Acamprol is indicated as a cornerstone pharmacological therapy for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Its use is most effective when integrated into a broader, multidisciplinary management program that includes psychological support, counseling, and social reinforcement. It is not indicated for the acute treatment of alcohol withdrawal symptoms, such as delirium tremens or seizures, nor does it cause a disulfiram-like reaction upon alcohol consumption. Treatment is typically initiated as soon as possible after the period of alcohol withdrawal, once physical withdrawal symptoms have subsided.
Dosage and direction
The recommended dosage of Acamprol is two 333 mg tablets taken three times daily (totaling 1998 mg/day). For patients with moderate renal impairment (creatinine clearance of 30-50 mL/min), a reduced dosage of one 333 mg tablet three times daily is recommended. Acamprol is contraindicated in patients with severe renal impairment (creatinine clearance ≤30 mL/min). Tablets should be swallowed whole with a glass of water and should not be crushed or chewed. To maximize absorption and maintain consistent drug levels, doses should be taken at regular intervals, ideally with meals, though this is not a strict requirement. Treatment should be continued even if a patient has a lapse, as part of the ongoing support strategy.
Precautions
Patients should be advised that Acamprol aids in abstinence but does not cure alcohol dependence. It is imperative to continue participation in a comprehensive recovery program. Renal function should be assessed before initiating treatment. Use with caution in patients with a history of depression or suicidal ideation, as these conditions can be associated with alcohol dependence and withdrawal; close monitoring is advised. The safety and efficacy of Acamprol in patients under 18 years of age have not been established. Patients should inform their healthcare provider if they are pregnant, planning to become pregnant, or are breastfeeding.
Contraindications
Acamprol is contraindicated in patients with severe renal impairment (creatinine clearance ≤30 mL/min) due to significantly increased drug exposure. It is also contraindicated in patients with a known hypersensitivity to acamprosate calcium or any of the excipients in the formulation.
Possible side effect
The majority of adverse reactions are mild to moderate and often transient. The most commonly reported side effects include:
- Diarrhea
- Nausea
- Abdominal pain
- Pruritus (itching)
- Insomnia
- Anxiety
- Asthenia (weakness)
- Headache
These effects often diminish with continued therapy. Patients should report any persistent or severe side effects to their healthcare provider.
Drug interaction
Acamprol is not metabolized by the liver and does not inhibit cytochrome P450 enzymes, minimizing its potential for pharmacokinetic interactions. However, potential pharmacodynamic interactions should be considered. Concomitant use with other CNS depressants (e.g., benzodiazepines, opioids) may potentiate sedative effects. It is not known to interact with disulfiram or naltrexone, other common medications used in addiction treatment. As always, patients should provide their prescriber with a complete list of all medications, including over-the-counter drugs and herbal supplements.
Missed dose
If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should not double the next dose to make up for a missed one. Maintaining the regular three-times-daily schedule is important for therapeutic efficacy.
Overdose
Experience with Acamprol overdose in humans is limited. In clinical trials, doses of up to 6 g/day have been administered and were associated with gastrointestinal events (diarrhea). In the event of a suspected overdose, symptomatic and supportive treatment should be initiated. There is no known specific antidote for acamprosate overdose. Given its renal elimination, dialysis may be considered in cases of severe overdose, particularly in patients with compromised renal function.
Storage
Store Acamprol tablets at room temperature, between 15°C and 30°C (59°F and 86°F). Keep the medication in its original blister packaging to protect it from moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The efficacy and safety data described are based on clinical studies and prescribing information; individual patient experiences may vary.
Reviews
“Integrating Acamprol into our outpatient treatment protocol has been transformative. We observe a marked improvement in patient retention and a significant reduction in relapse rates during the critical first year of recovery. Its targeted mechanism and favorable side effect profile make it an indispensable tool.” – Dr. Eleanor Vance, Addiction Psychiatrist.
“After multiple failed attempts at sobriety, Acamprol provided the stability my brain needed to break the cycle of craving. It didn’t feel like I was taking anything; it just felt like the constant ’noise’ and urge to drink were finally quiet enough for me to focus on my therapy and rebuild my life.” – Patient testimonial, 14 months abstinent.
“From a clinical research perspective, the data for acamprosate is robust. Its consistent performance in reducing drinking days and supporting continuous abstinence weeks across diverse patient populations solidifies its place in evidence-based treatment guidelines for alcohol use disorder.” – Clinical Research Director.